International Journal of Clinical Pharmacokinetics and Medical Sciences

A review on triggering factors and causes of infertility

Fri, 04 Oct 2024 00:00:00 +0530

Infertility affects approximately 10-15% of men and women worldwide, and it is influenced by a variety of factors. These include age, family history, nutrition, body weight, exercise habits, psychological stress, hormonal imbalances, and environmental factors. While infertility is often viewed as a physical condition, it also has profound emotional and psychological implications, impacting overall well-being.Individuals struggling with infertility, especially women, are more likely to experience mental health challenges, such as depression, anxiety, and stress. Infertile women often report a significantly lower quality of life compared to their fertile counterparts, with many experiencing feelings of inadequacy, grief, and isolation. About 23% of women facing infertility are diagnosed with anxiety disorders, highlighting the emotional toll the condition takes.The psychological impact is further intensified after failed fertility treatments like in vitro fertilization (IVF). Unsuccessful IVF attempts can lead to a sense of hopelessness, deepening depression, and anxiety, complicating the emotional landscape. Because of the mental health challenges associated with infertility, it is crucial to provide comprehensive care that includes emotional support. Addressing the psychological aspects of infertility alongside physical treatment can improve patients’ well-being, making it a vital part of holistic infertility management. Supporting emotional health is essential to help individuals cope with the emotional burden infertility brings.

Development and bioavailability improvement of Resiquimod in the form of solid lipid nanoparticles

Arava sravanthi, M Pradeep Kumar, C Manjula, B Jagadeesh Babu — Tue, 01 Oct 2024 00:00:00 +0530

The present study aims to develop Resiquimod's Solid Lipid Nanoparticles (SLNs) for topical drug delivery. To evaluate the physicochemical characterization of Resiquimod, lipids, polymers, surfactants & other additives. Formulation & Evaluation of SLNs for particle size analysis, Zeta potential, entrapment efficiency, polydispersity index (PDI), and % yield of produced SLNs. Based on the current studies, it can be said that Resiquimod solid lipid nanoparticles were effectively created and optimized. Hydrogels of prepared SLNs can be applied topically to treat skin conditions such as actinic keratoses (AKs). Different concentrations of lipids and surfactants were used to design SLNs. Mannitol showed much effectiveness as a Cryoprotectant. The drug's excipient Research on the compatibility of drugs, lipids, polymers, and their combinations using FTIR and DSC confirms that the drugs and excipients do not interact chemically. The Nanoparticles in the SLN droplets were intact, non-aggregated, and almost spherical according to scanning electron microscopy (SEM) pictures. The particle size of SLNs loaded with Resiquimod ranges from 208 to 503 nm. This could contribute to the SLNs' more extended blood circulation period. It was discovered that the PDI was less than 0.6. Adequate stability was demonstrated by the negative charge of the zeta potential in the formulation of SLNs. The results are encouraging and represent a novel contribution of Resiquimod SLNs in Topical Drug Delivery.

Actd regulatory requirements for approving an anticancer drug (thioguanine)

Wed, 02 Oct 2024 00:00:00 +0530

This work makes document handling safer and more accessible. It can manage even more complex papers in addition to all the benefits. Using this work, a composite document or papers from several different document sources and formats can be assembled, updated, and published. Each document is treated as a single, identically organized document. BMR, Process Validation Record, Stability Study (including Accelerated & Long Term Stability Study per Myanmar Zone Specification), Anticancer Drug Packing Requirements, and Certificate for Product Permission (covering all aspects from manufacturing to its packing & registration) are among the required documents. It offers reliable scientific methods for determining the effectiveness, safety, and quality of medicinal items. It will assist in comprehending the documentation needs for drug registration in Myanmar.